usp专利下载

1、USP是什么意思？？

usp策略——罗瑟·瑞夫斯《实效广告》
即“独特的销售主张（unique sales proposition）”
1.每一则广告必须向消费者“说一个主张，必须让消费者明白购买广告中的产品可以获得什么具体利益”；
2.所强调的主张必须是竞争对手做不到的或者无法提供的，必须说出其独特之处，在品牌和诉求方面是独一无二的；
3.所强调的主张必须是强而有力的，必须聚集在一个点上，集中打动，感动和引导消费者来买相应的产品。

2、USP是什么意思?

usp美国药典，目前有两种定义。

一种是美联邦对药品质量标准和检定方法作出的技术规定的作为一个独立的、非盈利性的非政府组织。USP发布的标准已被全球130多个国家(地区)所认同。

第二种是上面介绍定义的机构出版物usp美国药典。

usp美国药典是美联邦对药品质量标准和检定方法作出的技术规定，是企业、单位、机构等生产、使用、管理、检验药品、化学品、化工品的法律依据。

(2)usp专利下载扩展资料

usp在中国

由于中国医药企业的迅猛发展，usp美国药典也于2007年在中国设立总部，正式征战大中华地区的认证业务。

3、电脑主机上的USP是什么???

USP：United States Patent 美国专利
USP：United States Pharmacopoeia 美国药典
USP：User Stack Pointer 用户堆栈指针
USP：Universal Selbstlade Pistol 通用自动装填手枪
USP：Unique Selling Proposition 独特销售主张
USP：University of the South Pacific 南太平洋大学
USP：University of São Paulo 圣保罗大学
USP：University of the Sciences in Philadelphia 费城理科大学

不知道你的电脑主机上的USP代表的是何种意思。

4、求高手查一下这个专利，公开号：us2145952A。最好有文档

Bibliographic data: US2145952 (A) ― 1939-02-07

这个老美的专利时间可有点久哦，看看是不是这个？

优先权日期都是1937年了。。。

名称是 Vehicle bumper。

下载地址：

http://www4.drugfuture.com/uspat/download/US2145952.pdf

不用谢我，请叫我雷锋~

5、USP的英文全称

USP即“独特的销售主张”(Unique Selling Proposition)表示
独特的销售主张或“独特的卖点”，“USP”是罗瑟·瑞夫斯（Rosser Reeves）在20世纪50年代首创的，他当时是美国Ted Bates广告公司董事长。里夫斯比较早地意识到广告必须引发消费者的认同。他认为，USP是消费者从广告中得到的东西，而不是广告人员硬性赋予广告的东西

6、usp是什么意思？

1、USP

英文缩写：USP

英文全称：US Patent

中文解释：美国专利

缩写分类：自科总论、常用词汇

缩写简介：The United States Patent美国专利

2、USP

英文缩写：USP

英文全称：The united states pharmacopoeia

中文解释：《美国药典》

缩写分类：医药卫生

3、USP

英文缩写：USP

英文全称：unique selling proposition

中文解释：独特销售理论

缩写分类：经济管理

4、usp

英文缩写：usp

英文全称：Universal Selbstlade Pistole

中文解释：通用自动装填手枪

缩写分类：军事政治

(6)usp专利下载扩展资料：

重点词汇：united

英［ju＇naɪtɪd］

释义：

adj.一致的，统一的；团结的，和睦的

短语：

United Kingdom英国；联合王国；最尊崇天才的英国；国家

7、usp对照品说明书如何下载

USP对照品说明书可以自助查询，

首先进入USP网站，然后在搜索框内输入您需要查询产品的编号，比如1000829

然后点击搜索就会得到相应的产品信息，说明书也包含在内

8、美国药典中文版下载

5月16日 15:46 现行为USP 29-NF 24

USP 29-NF 24 的正式有效日期是 2006 年 1 月 1 日至 2006 年 12 月 31 日。

具体可参考美国药典网站，现已有中文网页：http://www.usp.org/USPNF/

9、急求:所谓的美国专利USP4493902的具体内容是什么??

United States Patent 4,493,902
Brown , et al. January 15, 1985

--------------------------------------------------------------------
Fluid catalytic cracking catalyst comprising microspheres containing more than about 40 percent by weight Y-faujasite and methods for making

Abstract
This application discloses novel fluid catalytic cracking catalysts comprising microspheres containing more than about 40%, preferably 50-70%, by weight Y-faujasite zeolite, methods for making such catalysts, and the use of such catalysts to crack petroleum feedstocks, particularly those containing large amounts of contaminant metals. The microspheres of the catalyst of the invention are characterized by a combination of desirable catalytic and physical characteristics, including exceptionally high activity, excellent hydrothermal stability, good to excellent attrition resistance, and desirable selectivity characteristics.

--------------------------------------------------------------------------------
Inventors: Brown; Stanley M. (Scotch Plains, NJ), Durante; Vincent A. (East Brunswick, NJ), Reagan; William J. (Englishtown, NJ), Speronello; Barry K. (River Edge, NJ)
Assignee: Engelhard Corporation (Iselin, NJ)

Appl. No.: 06/469,765
Filed: February 25, 1983

--------------------------------------------------------------------------------

详细内容不介绍了，美国国家专利局网站就免费提供全文（full text），含图的，自己下载看看：
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4493902.PN.&OS=PN/4493902&RS=PN/4493902

10、请问，谁能下载到USP35 1225 VERIFICATION OF COMPENDIAL PROCEDURES的内容？

1226 VERIFICATION OF COMPENDIAL PROCEDURES
The intent of this general information chapter is to provide general information on the verification of compendial proceres that are being performed for the first time to yield acceptable results utilizing the personnel, equipment, and reagents available. This chapter is not intended for retroactive application to already successfully established laboratory proceres. The chapter Validation of Compendial Proceres 1225 provides general information on characteristics that should be considered for various test categories and on the documentation that should accompany analytical proceres submitted for inclusion in USP–NF. Verification consists of assessing selected analytical performance characteristics, such as those that are described in chapter 1225, to generate appropriate, relevant data rather than repeating the validation process.
Users of compendial analytical proceres are not required to validate these proceres when first used in their laboratories, but documented evidence of suitability should be established under actual conditions of use. In the United States, this requirement is established in 21 CFR 211.194(a)(2) of the current Good Manufacturing Practice regulations, which states that the “suitability of all testing methods used shall be verified under actual conditions of use.”
Verification of microbiological proceres is not covered in this chapter because it is covered in USP general test chapters Antimicrobial Effectiveness Testing 51, Microbiological Examination of Nonsterile Procts: Microbial Enumeration Tests 61, Microbiological Examination of Nonsterile Procts: Tests for Specified Microorganisms 62, Sterility Tests 71, and in general information chapter Validation of Microbial Recovery from Pharmacopeial Articles 1227.
Change to read:

VERIFICATION PROCESS
The verification process for compendial test proceres is the assessment of whether the procere can be used for its intended purpose, under the actual conditions of use for a specified drug substance and/or drug proct matrix.USP35
Users should have the appropriate experience, knowledge, and training to understand and be able to perform the compendial proceres as written. Verification should be concted by the user such that the results will provide confidence that the compendial procere will perform suitably as intended.
If the verification of the compendial procere is not successful, and assistance from USP staff has not resolved the problem, it may be concluded that the procere may not be suitable for use with the article being tested in that laboratory. It may then be necessary to develop and validate an alternate procere as allowed in the General Notices. The alternate procere may be submitted to USP, along with the appropriate data, to support a proposal for inclusion or replacement of the current compendial procere.
Change to read:

VERIFICATION REQUIREMENTS
Verification requirements should be based on an assessment of the complexity of both the procere and the material to which the procere is applied. Although complete revalidation of a compendial method is not required to verify the suitability of a procereUSP35 under actual conditions of use, some of the analytical performance characteristics listed in chapter 1225, Table 2, may be used for the verification process. Only those characteristics that are considered to be appropriate for the verification of the particular procereUSP35 need to be evaluated. The process of assessing the suitability of a compendial analytical test procere under the conditions of actual use may or may not require actual laboratory performance of each analytical performance characteristic.USP35 The degree and extent of the verification process may depend on the level of training and experience of the user, on the type of procere and its associated equipment or instrumentation, on the specific proceral steps, and on which article(s) are being tested.
Verification should assess whether the compendial procere is suitable for the drug substance and/or the drug proct matrix, taking into account the drug substance's synthetic route, the method of manufacture for the drug proct, or both, if applicable. Verification should include an assessment of elements such as the effect of the matrix on the recovery of impurities and drug substances from the drug proct matrix, as well as the suitability of chromatographic conditions and column, the appropriateness of detector signal response, etc.USP35
As an example, an assessment of specificity is a key parameter in verifying that a compendial procere is suitable for use in assaying drug substances and drug procts. For instance, acceptable specificity for a chromatographic method may be verified by conformance with system suitability resolution requirements (if specified in the procere).USP35 However, drug substances from different suppliers may have different impurity profiles that are not addressed by the compendial test procere. Similarly, the excipients in a drug proct can vary widely among manufacturers and may have the potential to directly interfere with the procere or cause the formation of impurities that are not addressed by the compendial procere. In addition, drug procts containing different excipients, antioxidants, buffers, or container extractives may affect the recovery of the drug substance from the matrix.USP35 In these cases, a more thorough assessment of the matrix effectsUSP35 may be required to demonstrate suitability of the procereUSP35 for the particular drug substance or proct. Other analytical performance characteristics such as an assessment of the limit of detection or quantitation and precision for impurities proceres may be useful to demonstrate the suitability of the compendial procereUSP35 under actual conditions of use.
Verification is not required for basic compendial test proceres that are routinely performed unless there is an indication that the compendial procere is not appropriate for the article under test. Examples of basic compendial proceres include, but are not limited to, loss on drying, resie on ignition, various wet chemical proceres such as acid value, and simple instrumental determinationsUSP35 such as pH measurements. However, for the application of already established routine proceres to compendial articles tested for the first time, it is recommended that consideration be given to any new or different sample handling or solution preparation requirements.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
General Chapter Horacio N. Pappa, Ph.D.
Principal Scientific Liaison
1-301-816-8319 (GCPA2010) General Chapters - Physical Analysis

USP35–NF30 Page 882
Pharmacopeial Forum: Volume No. 36(6) Page 1775

1226是VERIFICATION &1225是VALIDATION ，跟您的提问有点出入，本想两个都贴上来，可是奈何篇幅太长，知道发不出。
1226&1225具体内容已发送至邮箱，请查收！